Publications by authors named "U Lassen"
Magnetic resonance imaging and o-(2-[F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.
Neurooncol Adv
October 2024
Background: In the present study, early response assessment by o-(2-[F]fluoroethyl)-l-tyrosine (FET) positron emission tomography (PET) and contrast-enhanced magnetic resonance imaging (MRI) were investigated in a phase II open-label single-center study of nivolumab plus bevacizumab for recurrent high-grade astrocytic glioma.
Methods: Twenty patients with nonresectable first recurrence of high-grade astrocytic glioma after EORTC/NCIC protocol underwent [F]FET PET/MRI at baseline and after 2 cycles of treatment. Whole brain values of contrast-enhancing volume on MRI (CEV), of the mean (TBR) and maximal tumor-to-background ratio (TBR), and of metabolically active volume (MTV) on [F]FET PET were obtained.
Background: Breast cancer is the most common cancer in women, and the first-line treatment for patients with hormone-receptor positive/HER2-negative metastatic breast cancer is CDK4/6 inhibitor plus endocrine therapy. Understanding the impact of CDK4/6 inhibitor dose reduction, which occurs in about half of the patients, is important.
Methods: This real-world cohort study is based on electronic health records from Capital Region of Denmark.
Purpose: There is an unmet need for new treatment options and biomarkers for patients with glioblastoma (GBM). Here we investigated three non-invasive biomarkers: type VI collagen degraded by granzyme B (C4G) and matrix metalloproteases (C4M), respectively, and ADAM10-degraded Tau (Tau-A).
Methods: Biomarker levels in pre- and on-treatment serum samples from patients with recurrent GBM (n = 39) treated with nivolumab and bevacizumab (NCT03890952) were compared to healthy levels (n = 22) and associated with overall survival (OS) outcome (median cutpoint).
Article Synopsis
- Researchers analyzed genetic data from nearly 130,000 cancer patients and over 730,000 healthy controls to identify variants linked to cancer risk across 22 cancer types.
- Four high-risk genes were found: BIK (prostate cancer), ATG12 (colorectal cancer), TG (thyroid cancer), and CMTR2 (lung cancer and melanoma).
- Additionally, two genes, AURKB (general cancer risk) and PPP1R15A (breast cancer), were associated with decreased cancer risk, indicating potential pathways for cancer prevention strategies.
Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options.
Objective: Considering the hypothesis that central hubs are associated with increased lethality, identifying key hub targets within central networks could lead to the development of novel drugs with improved efficacy in advanced metastatic solid tumors.